|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C3orf67 |
Gene summary for C3ORF67 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C3orf67 | Gene ID | 200844 |
| Gene name | CFAP20 domain containing | |
| Gene Alias | C3orf67 | |
| Cytomap | 3p14.2 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q6ZVT6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 200844 | C3orf67 | LZE4T | Human | Esophagus | ESCC | 3.18e-05 | 1.69e-01 | 0.0811 |
| 200844 | C3orf67 | LZE24T | Human | Esophagus | ESCC | 1.89e-10 | 2.97e-01 | 0.0596 |
| 200844 | C3orf67 | P2T-E | Human | Esophagus | ESCC | 1.28e-06 | 1.94e-01 | 0.1177 |
| 200844 | C3orf67 | P4T-E | Human | Esophagus | ESCC | 7.21e-12 | 2.53e-01 | 0.1323 |
| 200844 | C3orf67 | P5T-E | Human | Esophagus | ESCC | 4.34e-07 | 1.36e-01 | 0.1327 |
| 200844 | C3orf67 | P9T-E | Human | Esophagus | ESCC | 2.41e-06 | 1.75e-01 | 0.1131 |
| 200844 | C3orf67 | P12T-E | Human | Esophagus | ESCC | 5.25e-16 | 2.79e-01 | 0.1122 |
| 200844 | C3orf67 | P15T-E | Human | Esophagus | ESCC | 5.26e-03 | 9.13e-02 | 0.1149 |
| 200844 | C3orf67 | P20T-E | Human | Esophagus | ESCC | 9.54e-15 | 3.11e-01 | 0.1124 |
| 200844 | C3orf67 | P21T-E | Human | Esophagus | ESCC | 1.23e-11 | 2.97e-01 | 0.1617 |
| 200844 | C3orf67 | P22T-E | Human | Esophagus | ESCC | 1.06e-07 | 1.68e-01 | 0.1236 |
| 200844 | C3orf67 | P23T-E | Human | Esophagus | ESCC | 4.97e-06 | 1.64e-01 | 0.108 |
| 200844 | C3orf67 | P26T-E | Human | Esophagus | ESCC | 3.55e-03 | 1.38e-01 | 0.1276 |
| 200844 | C3orf67 | P27T-E | Human | Esophagus | ESCC | 2.61e-05 | 1.64e-01 | 0.1055 |
| 200844 | C3orf67 | P28T-E | Human | Esophagus | ESCC | 8.53e-04 | 1.14e-01 | 0.1149 |
| 200844 | C3orf67 | P30T-E | Human | Esophagus | ESCC | 1.72e-15 | 4.36e-01 | 0.137 |
| 200844 | C3orf67 | P31T-E | Human | Esophagus | ESCC | 1.25e-10 | 2.33e-01 | 0.1251 |
| 200844 | C3orf67 | P32T-E | Human | Esophagus | ESCC | 1.10e-14 | 3.48e-01 | 0.1666 |
| 200844 | C3orf67 | P36T-E | Human | Esophagus | ESCC | 2.98e-06 | 1.84e-01 | 0.1187 |
| 200844 | C3orf67 | P37T-E | Human | Esophagus | ESCC | 1.93e-09 | 1.95e-01 | 0.1371 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C3orf67 | SNV | Missense_Mutation | c.1088N>T | p.Pro363Leu | p.P363L | Q6ZVT6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| C3orf67 | SNV | Missense_Mutation | c.1171N>C | p.Asp391His | p.D391H | Q6ZVT6 | protein_coding | deleterious(0.03) | possibly_damaging(0.724) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| C3orf67 | SNV | Missense_Mutation | rs773017513 | c.289N>T | p.Arg97Cys | p.R97C | Q6ZVT6 | protein_coding | tolerated(0.07) | possibly_damaging(0.88) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C3orf67 | SNV | Missense_Mutation | c.899N>T | p.Pro300Leu | p.P300L | Q6ZVT6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| C3orf67 | SNV | Missense_Mutation | novel | c.574N>G | p.Pro192Ala | p.P192A | Q6ZVT6 | protein_coding | tolerated(0.41) | benign(0) | TCGA-LL-A8F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| C3orf67 | insertion | Nonsense_Mutation | novel | c.1300_1301insTACAAGAGGCTCAATATTTGTTAAATAAGTATTTATGAAATGAATG | p.Asn434IlefsTer13 | p.N434Ifs*13 | Q6ZVT6 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| C3orf67 | SNV | Missense_Mutation | c.1318N>T | p.Ala440Ser | p.A440S | Q6ZVT6 | protein_coding | tolerated(0.26) | benign(0) | TCGA-C5-A7X3-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | |
| C3orf67 | SNV | Missense_Mutation | c.787G>C | p.Glu263Gln | p.E263Q | Q6ZVT6 | protein_coding | tolerated(0.17) | benign(0.221) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| C3orf67 | SNV | Missense_Mutation | rs369398734 | c.1198G>A | p.Gly400Ser | p.G400S | Q6ZVT6 | protein_coding | tolerated(0.06) | benign(0.065) | TCGA-UC-A7PD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| C3orf67 | SNV | Missense_Mutation | rs772778129 | c.1546N>T | p.Arg516Cys | p.R516C | Q6ZVT6 | protein_coding | tolerated(0.21) | benign(0) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |